Divi's Laboratories Limited reported revenue from operations of Rs 2,793 crore for the year ended March 31, 2026, up from Rs 2,578 crore in the prior year. Profit before tax stood at Rs 971 crore, driven by operational growth. An exceptional item of Rs 74 crore was recorded due to increased employee benefits expenses under new labour codes notified in November 2025.
The board proposed a final dividend of Rs 30 per equity share for fiscal 2025-26, representing 1,500% of the Rs 2 face value. This recommendation requires shareholder approval at the 36th Annual General Meeting (AGM) on August 10, 2026, with a record date of July 24, 2026. The dividend payment will follow AGM conclusions within specified timelines.
Divi's Laboratories Limited operates in a single business segment focused on pharmaceutical ingredients and nutraceuticals. The company continues to assess the financial impact of labour code implementations and will update disclosures as required by regulations. The Rs 74 crore exceptional item reflects adjustments for incremental employee benefits costs under the new labour codes.
Financial results for the year ended March 31, 2026, include a profit before tax of Rs 971 crore. The standalone audited financial statements confirm revenue growth and compliance with SEBI disclosure requirements. The company’s cash flow from operations increased to Rs 2,711 crore, supporting its dividend proposal and operational expansion.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.